Functional Testing of an Inhalable Nanoparticle Based Influenza Vaccine Using a Human Precision Cut Lung Slice Technique

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Neuhaus, Vanessa ^a,f   Schwarz, Katharina ^a,f   Klee, Anna ^a,f   Seehase, Sophie ^b,f   Förster, Christine ^c   Pfennig, Olaf ^c   Jonigk, Danny ^d,f   Fieguth, Hans Gerd ^c   Koch, Wolfgang ^a,f   Warnecke, Gregor ^d,f   Yusibov, Vidadi ^e   Sewald, Katherina ^a,f   Braun, Armin ^a,d,f  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

^c Klinikum Oststadt Heidehaus   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e USA Center for Molecular Biotechnology   (United States)

^f German Center for Lung Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 8; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD3+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; INFLUENZA; INNATE IMMUNITY; LUNG SLICE; QUANTITATIVE ANALYSIS; SEASONAL INFLUENZA; TOXICITY TESTING; VIRUS ENTRY; VIRUS STRAIN; ZOONOSIS;

ADMINISTRATION, INHALATION; CYTOKINES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLAMMATION MEDIATORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; NANOCONJUGATES; SILICON DIOXIDE; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881489356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071728     Document Type: Article

References (48)

1. World health organization website (2009) Influenza (Seasonal); Fact sheet N°211. Available: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed: 23-2-2013.
2. Bulletin of the World health organization (1980) A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull World Health Organ 58: 585-591.
3. Gupta V, Earl DJ, Deem MW, (2006) Quantifying influenza vaccine efficacy and antigenic distance. Vaccine 24: 3881-3888 S0264-410X(06)00004-1 [pii];10.1016/j.vaccine.2006.01.010 [doi].
4. Thangavel RR, Reed A, Norcross EW, Dixon SN, Marquart ME, et al. (2011) "Boom" and "Bust" cycles in virus growth suggest multiple selective forces in influenza a evolution. Virol J 8: 180 1743-422X-8-180 [pii];10.1186/1743-422X-8-180 [doi].
5. Pereira HG, Rinaldi A, Nardelli L, (1967) Antigenic variation among avian influenza A viruses. Bull World Health Organ 37: 553-558.
6. Gamblin SJ, Skehel JJ, (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285: 28403-28409 R110.129809 [pii];10.1074/jbc.R110.129809 [doi].
7. Claas EC (2000) Pandemic influenza is a zoonosis, as it requires introduction of avian-like gene segments in the human population. Vet Microbiol 74: 133-139. S0378-1135(00)00173-5 [pii].
8. Juno J, Fowke KR, Keynan Y, (2012) Immunogenetic factors associated with severe respiratory illness caused by zoonotic H1N1 and H5N1 influenza viruses. Clin Dev Immunol 2012: 797180 10.1155/2012/797180 [doi].
9. Mortimer E, Maclean JM, Mbewana S, Buys A, Williamson AL, et al. (2012) Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC Biotechnol 12: 14 1472-6750-12-14 [pii];---10.1186/1472-6750-12-14 [doi].
10. Ulmer JB, Valley U, Rappuoli R, (2006) Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24: 1377-1383 nbt1261 [pii];10.1038/nbt1261 [doi].
11. Shoji Y, Farrance CE, Bautista J, Bi H, Musiychuk K, et al. (2012) A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respi Viruses 6: 204-210 -10.1111/j.1750-2659.2011.00295.x [doi].
12. Chichester JA, Yusibov V (2007) Plants as alternative systems for production of vaccines. Hum Vaccin 3: 146-148. 4148 [pii].
13. Shoji Y, Chichester JA, Bi H, Musiychuk K, de la Rosa P, et al. (2008) Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 26: 2930-2934 S0264-410X(08)00369-1 [pii];10.1016/j.vaccine.2008.03.045 [doi].
14. Koutsonanos DG, del Pilar MM, Zarnitsyn VG, Jacob J, Prausnitz MR, et al. (2011) Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis 204: 582-591 jir094 [pii];10.1093/infdis/jir094 [doi].
15. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, et al. (1994) Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A 91: 9519-9523.
16. Holmgren J, Svennerholm AM (2012) Vaccines against mucosal infections. Curr Opin Immunol. S0952-7915(12)00063-5 [pii];10.1016/j.coi.2012.03.014 [doi].
17. Tumpey TM, Renshaw M, Clements JD, Katz JM, (2001) Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75: 5141-5150 10.1128/JVI.75.11.5141-5150.2001 [doi].
18. Madhun AS, Haaheim LR, Nostbakken JK, Ebensen T, Chichester J, et al. (2011) Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine 29: 4973-4982 S0264-410X(11)00649-9 [pii];10.1016/j.vaccine.2011.04.094 [doi].
19. Wee JL, Scheerlinck JP, Snibson KJ, Edwards S, Pearse M, et al. (2008) Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol 1: 489-496 mi200859 [pii];10.1038/mi.2008.59 [doi].
20. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP, (2005) Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57: 391-410 S0169-409X(04)00209-1 [pii];10.1016/j.addr.2004.09.003 [doi].
21. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70: 1-20. S0168365900003394 [pii].
22. Carvalho LV, Ruiz RC, Scaramuzzi K, Marengo EB, Matos JR, et al. (2010) Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. Vaccine 28: 7829-7836 S0264-410X(10)01429-5 [pii];10.1016/j.vaccine.2010.09.087 [doi].
23. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, et al. (2007) N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 25: 144-153 S0264-410X(06)00879-6 [pii];10.1016/j.vaccine.2006.06.086 [doi].
24. Richert LE, Servid AE, Harmsen AL, Rynda-Apple A, Han S, et al. (2012) A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine 30: 3653-3665 S0264-410X(12)00411-2 [pii];10.1016/j.vaccine.2012.03.035 [doi].
25. Barnard DL, (2009) Animal models for the study of influenza pathogenesis and therapy. Antiviral Res 82: A110-A122 S0166-3542(09)00018-7 [pii];10.1016/j.antiviral.2008.12.014 [doi].
26. Christensen D, Foged C, Rosenkrands I, Lundberg CV, Andersen P, et al. (2010) CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int J Pharm 390: 19-24 S0378-5173(09)00769-8 [pii];10.1016/j.ijpharm.2009.10.043 [doi].
27. Switalla S, Lauenstein L, Prenzler F, Knothe S, Forster C, et al. (2010) Natural innate cytokine response to immunomodulators and adjuvants in human precision-cut lung slices. Toxicol Appl Pharmacol. S0041-008X(10)00137-7 [pii];10.1016/j.taap.2010.04.010 [doi].
28. Wu W, Booth JL, Duggan ES, Wu S, Patel KB, et al. (2010) Innate immune response to H3N2 and H1N1 influenza virus infection in a human lung organ culture model. Virology 396: 178-188 S0042-6822(09)00625-4 [pii];10.1016/j.virol.2009.10.016 [doi].
29. Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, et al. (2011) Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 7 Suppl: 41-50. 14561 [pii].
30. Jul-Larsen A, Madhun A, Brokstad K, Montomoli E, Yusibov V, et al. (2012) The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. Hum Vaccin Immunother 8. 19503 [pii].
31. Wohlsen A, Martin C, Vollmer E, Branscheid D, Magnussen H, et al. (2003) The early allergic response in small airways of human precision-cut lung slices. Eur Respir J 21: 1024-1032.
32. Chazaud C, Yamanaka Y, Pawson T, Rossant J, (2006) Early lineage segregation between epiblast and primitive endoderm in mouse blastocysts through the Grb2-MAPK pathway. Dev Cell 10: 615-624 S1534-5807(06)00125-0 [pii];10.1016/j.devcel.2006.02.020 [doi].
33. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952 NEJMoa0906453 [pii];10.1056/NEJMoa0906453 [doi].
34. Centers for Disease Control and Prevention (2009) Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1)- United States, May-June 2009. MMWR Morb Mortal Wkly Rep 58: 1241-1245. mm5844a5 [pii].
35. van Riel D, Munster VJ, de WE, Rimmelzwaan GF, Fouchier RA, et al. (2006) H5N1 Virus Attachment to Lower Respiratory Tract. Science 312: 399 1125548 [pii];10.1126/science.1125548 [doi].
36. Mancino D, Ovary Z, (1980) Adjuvant effects of amorphous silica and of aluminium hydroxide on IgE and IgG1 antibody production in different inbred mouse strains. Int Arch Allergy Appl Immunol 61: 253-258.
37. Mancino D, Bevilacqua N, (1977) Adjuvant effect of amorphous silica on the immune response to various antigens in guinea pigs. Int Arch Allergy Appl Immunol 53: 97-103.
38. Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, et al. (2010) Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci U S A 107: 19449-19454 1008155107 [pii];10.1073/pnas.1008155107 [doi].
39. Winter M, Beer HD, Hornung V, Kramer U, Schins RP, et al. (2011) Activation of the inflammasome by amorphous silica and TiO2 nanoparticles in murine dendritic cells. Nanotoxicology 5: 326-340 10.3109/17435390.2010.506957 [doi].
40. Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, et al. (2012) T-Helper 1 Cells Elicited by H5N1 Vaccination Predict Seroprotection. J Infect Dis 206: 158-166 jis330 [pii];10.1093/infdis/jis330 [doi].
41. Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, et al. (2009) Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27: 5956-5963 S0264-410X(09)01119-0 [pii];10.1016/j.vaccine.2009.07.081 [doi].
42. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, et al. (1997) Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 159: 105-117.
43. Zhu J, Paul WE, (2010) Heterogeneity and plasticity of T helper cells. Cell Res 20: 4-12 cr2009138 [pii];10.1038/cr.2009.138 [doi].
44. Riberdy JM, Christensen JP, Branum K, Doherty PC, (2000) Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J Virol 74: 9762-9765.
45. Topham DJ, Tripp RA, Doherty PC, (1997) CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159: 5197-5200.
46. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL, (2010) Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 84: 9217-9226 JVI.01069-10 [pii];-10.1128/JVI.01069-10 [doi].
47. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrancois L, et al. (2011) Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 187: 5510-5514 jimmunol.1102243 [pii];10.4049/jimmunol.1102243 [doi].
48. Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, et al. (2011) Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS One 6: e16245 10.1371/journal.pone.0016245 [doi].